Fol News

Tutti gli approfondimenti
Tutte le notizie

CRIS - Possible take over by Roche...

mastrodaniel

mastrodaniel

Nuovo Utente
Registrato
21/9/05
Messaggi
6.012
Punti reazioni
247
curis inc (cris)

che dite si puo tentare un cippetto....graficamente non mi pare male....aspetto cosiderazioni...saluti
 
CRIS e DCGN che ne dite?

Ciao ragazzi, che ne dite di questi due titoli ?
Hi visto le pipeline, non sembrano male

deCODE genetics, Inc.
Curis, Inc.

Che ne dite?
Avete un qualche ciccha da consigliare?

ciao :)
 
Cris

Genentech, Inc. Announces Potential Skin Cancer Breakthrough Tested At Scottsdale Healthcare Published In New England Journal of Medicine
Wednesday, 2 Sep 2009 05:00pm EDT
Genentech, Inc. announced that a study published in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients. The article appears online at NEJM.org and will be included in the September 17, issue of New England Journal of Medicine. In a Phase I clinical trial conducted in Arizona at the Virginia G. Piper Cancer Center at Scottsdale Healthcare, Dr. Von Hoff and colleagues at Johns Hopkins University and Karmanos Cancer Institute demonstrated that GDC-0449, a Hedgehog Pathway Inhibitor, appears to shrink tumors in locally-advanced and metastatic basal cell carcinoma (BCC) while having limited side effects including a loss of sense of taste, and a small amount of hair loss and weight loss. GDC-0449 was discovered by Genentech and was jointly validated through a series of preclinical studies performed under a collaboration agreement between Genentech and Curis, Inc. Known as the Hedgehog trial, results suggest a durable clinical benefit, defined as tumor shrinkage visible on X-ray or other physical exam or improvement in symptoms without tumor growth, was observed in 18 of 33 patients evaluated.


ATTENZIONE AFTER A +30
OGGI POTREBBE VOLARE
 
laniero ha scritto:
Genentech, Inc. Announces Potential Skin Cancer Breakthrough Tested At Scottsdale Healthcare Published In New England Journal of Medicine
Wednesday, 2 Sep 2009 05:00pm EDT
Genentech, Inc. announced that a study published in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients. The article appears online at NEJM.org and will be included in the September 17, issue of New England Journal of Medicine. In a Phase I clinical trial conducted in Arizona at the Virginia G. Piper Cancer Center at Scottsdale Healthcare, Dr. Von Hoff and colleagues at Johns Hopkins University and Karmanos Cancer Institute demonstrated that GDC-0449, a Hedgehog Pathway Inhibitor, appears to shrink tumors in locally-advanced and metastatic basal cell carcinoma (BCC) while having limited side effects including a loss of sense of taste, and a small amount of hair loss and weight loss. GDC-0449 was discovered by Genentech and was jointly validated through a series of preclinical studies performed under a collaboration agreement between Genentech and Curis, Inc. Known as the Hedgehog trial, results suggest a durable clinical benefit, defined as tumor shrinkage visible on X-ray or other physical exam or improvement in symptoms without tumor growth, was observed in 18 of 33 patients evaluated.


ATTENZIONE AFTER A +30
OGGI POTREBBE VOLARE
Clicca per espandere...

come faccio a prenderle tramite banca ? che valore posso far mettere per non perderlo?
 
laniero ha scritto:
Genentech, Inc. Announces Potential Skin Cancer Breakthrough Tested At Scottsdale Healthcare Published In New England Journal of Medicine
Wednesday, 2 Sep 2009 05:00pm EDT
Genentech, Inc. announced that a study published in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients. The article appears online at NEJM.org and will be included in the September 17, issue of New England Journal of Medicine. In a Phase I clinical trial conducted in Arizona at the Virginia G. Piper Cancer Center at Scottsdale Healthcare, Dr. Von Hoff and colleagues at Johns Hopkins University and Karmanos Cancer Institute demonstrated that GDC-0449, a Hedgehog Pathway Inhibitor, appears to shrink tumors in locally-advanced and metastatic basal cell carcinoma (BCC) while having limited side effects including a loss of sense of taste, and a small amount of hair loss and weight loss. GDC-0449 was discovered by Genentech and was jointly validated through a series of preclinical studies performed under a collaboration agreement between Genentech and Curis, Inc. Known as the Hedgehog trial, results suggest a durable clinical benefit, defined as tumor shrinkage visible on X-ray or other physical exam or improvement in symptoms without tumor growth, was observed in 18 of 33 patients evaluated.


ATTENZIONE AFTER A +30
OGGI POTREBBE VOLARE
Clicca per espandere...

after giu' di brutto
 
spero non ci sia entrato nessuno in apertura.......
 
che schifo.
buttato ordine a 2,35 e venduto a 2,50.
mai piu'.
me la sono fatta addosso
erano 15.000 dollari investiti e ritirati in 38 minuti
ma ma ma ma mai piu'KO!
 
CRIS - this stock deserves your attention

Check this out : http://seekingalpha.com/article/160141-curis-cancer-therapy-arouses-curiosity#comments_header

CURIS INC.png

OK!
 
Maybe it is just a coincidence or not....

sc.jpg
 
Someone wants to buy a big block at 2.33
 
Please listen to this excellent presentation.
New info:

1) Curis is talking with several Asian pharmas about licensing CUDC-101 for Asia specific targets like stomach and liver cancer. YMI has done a similar thing with a Japanese pharma.

2) Multiple National Cancer Institute trials for Hedgehog, encouraged by Genentech, which may yield additional data in 2010. A nice wild card!

3) Curis characterized Hedgehog approval prospects for basal cell carcinoma as a "Low hanging fruit, Low-risk prospect."

Folks, Curis has so many irons in the fire that IT ONLY TAKES ONE to put the Curis brand on big dollars.

I would not wait too long to load up. CURIS is unlikely to go much lower, but could explode at any time, due to two more presentations this month.
 
IN pre oggi -38% fase II dello studio del farmaco fallita:eek:
 
visal ha scritto:
IN pre oggi -38% fase II dello studio del farmaco fallita:eek:
Clicca per espandere...
08:01 Curis annuncia Genentech Ph. risultati delle sperimentazioni cliniche II per GDC-0.449, in combinazione con Avastin e chemioterapia di prima linea nel carcinoma colorettale metastatico (CRIS) 3,26: Co annuncia topline risultati di uno studio clinico di fase II condotti da Roche e Genentech, collaboratore Curis 'ed è membro interamente controllata dal Gruppo Roche, di 0.449-GDC un first-in-classe degli inibitori pathway. GDC-0.449 è stato testato in combinazione con Avastin e chemioterapia FOLFOX o FOLFIRI in prima linea metastatico pazienti affetti da cancro colorettale. Roche ha informato Curis che il processo non ha raggiunto il suo endpoint primario di estendere il tempo trascorso dalla randomizzazione alla progressione della malattia o la morte in studio i pazienti che hanno ricevuto GDC-0.449 in aggiunta alla attuale standard di cura di bevacizumab e chemioterapia rispetto a quei pazienti che ricevuto solo l'attuale standard di trattamento di cura. GDC-0.449 è stato sviluppato da Roche e Genentech nel quadro di un accordo di collaborazione tra Curis e Genentech. Si prevede che i dati dello studio di Fase II sarà presentato per la presentazione in una riunione futuro medico
 
Cris.

Automatic intraday chart
z

Automatic charts in superior frames
chart.ashx
 
okkio scende -44%
Quasi quasi un giro sulla giostra me lo farei devo solo aspettare che vendo un titolo
 
.





up
up


2.795
 
Devi accedere o registrarti per poter rispondere.
Indietro